PHAR 402 Principles of Drug Action and Therapeutics II



SYLLABUS FOR

PRINCIPLES OF DRUG ACTION AND THERAPEUTICS II

PHAR 402

FALL SEMESTER 2012

|LECTURES | | |

|Meeting Days |Meeting Place |Meeting Time |

|Wed, Thurs |Room 134-3 (Chicago) |9:30 - 10:20 am |

| |Room E218 (Rockford) | |

|Fri |Room 134-3 Chicago |8:30 - 09:20 am |

| |Room E218 (Rockford) | |

|RECITATIONS | | |

|Tues |Rooms 470, 498, 570, 598, 134-3 |8:30 - 11:20 am |

| |(Chicago) | |

|Fri |Room E213, E216, E218, (Rockford) |9:30 - 12:20 pm |

| |Rooms 470, 498, 570, 598, 134-3 (Chicago) | |

| | | |

|COORDINATORS |Office and Office Hours |Email |

|Co-Coordinator: Norman L. Katz, PhD, RPh |Office: Room 235; Tel: 1-312- 996-0573 |E-mail: nlkatz@uic.edu |

|Professor of Pharmacology |Office Hours: Stop in, call or email to make an appointment| |

| | | |

|Co-Coordinator: TBA |Office: Room ; Tel: |E-mail: |

| |Office Hours: Stop in, call or email to make an appointment| |

| | | |

| | | |

| | | |

| | | |

COURSE OVERVIEW

[pic]

|Week |Date |Day |Lecture Topic |Lab/Discussion Topic |Faculty |

|1 |Aug 28 |T | |Lab/disc: Introduction to the course (9:30|Katz |

| | | | |today ONLY in 134-3 Chi) | |

|Lect 1 |Aug 29 |W |Introduction to the Nervous System | |Schlemmer |

|Lect 2 |Aug 30 |R |Medicinal Chemistry of the Cholinergic Nervous System | |Jaki |

| | | |I | | |

|Lect 3 |Aug 31 |F |Medicinal Chemistry of the Cholinergic Nervous System | |Jaki |

| | | |II | | |

| | |F | |Lab/disc: Introduction to the course |Katz |

| | | | |(9:30am; Rm 134-3 Chi; Rm E218Rkfd) | |

| |

|2 |Sept 04 |T | |Case study 1: Review of autonomic nervous |Schlemmer |

| | | | |system (8:30am;134-3 Chi) | |

|Lect 4 |Sept 05 |W |Pharmacology of Muscarinic Agonist Drugs | |Schlemmer |

|Lect 5 |Sep 06 |R |Pharmacology of Muscarinic Antagonist Drugs | |Schlemmer |

|Lect 6 |Sep 07 |F |Medicinal Chemistry of the Cholinergic Nervous System | |Jaki |

| | | |III | | |

| | |F | |Case study 1: Review of autonomic nervous |Schlemmer |

| | | | |system (9:30am; 134-3 Chi; E218Rkfd) | |

| |

|3 |Sep 11 |T | |Quiz 1 | |

| | | | |Case Study 2: Drugs acting on cholinergic |Katz/Jaki |

| | | | |nervous system (8:30am;134-3Chi) | |

|Lect 7 |Sep 12 |W |Adrenergic Nervous System | |Katz |

|Lect 8 |Sep 13 |R |Sites of Adrenergic Drug Action | |Orjala |

|Lect 9 |Sep 14 |F |Pharmacology of Adrenergic Agonist Drugs | |Katz |

| | |F | |Quiz 1 | |

| | | | |Case Study 2: Drugs acting on cholinergic |Katz/Jaki |

| | | | |nervous system (9:30am; 134-3 Chi; E218 | |

| | | | |Rkfd) | |

|Week |Date |Day |Lecture Topic |Lab/Discussion Topic |Faculty |

|Lect 10 |Sep 19 |W |Pharmacology of Adrenergic Antagonist Drugs | | Katz |

|Lect 11 |Sep 20 |R |Chemistry of Adrenergic Drugs | |Orjala |

|Lect 12 |Sep 21 |F |Pharmacology of Antihypertensive Drugs I | |Katz |

| | |F | |Quiz 2 |Katz/Orjala |

| | | | |Case Study 3: Drugs acting on adrenergic | |

| | | | |nervous system (9:30am 134-3 Chi; E218 | |

| | | | |Rkfd) | |

| |

|5 |Sep 25 |T | |Quiz 3 | |

| | | | |Case Study 4: Exam Review (134-3 Chi) |Staff |

|Lect 13 |Sep 26 |W |Pharmacology of Antihypertensive Drugs II | |Schlemmer |

|Lect 14 |Sep 27 |R |Chemistry of Antihypertensive Drugs I | |Orjala |

| |Sep 28 |F |Chemistry of Antihypertensive Drugs II | |Orjala |

| | |F | |Quiz 3 | |

| | | | |Case Study 4: Exam Review (134-3 Chi; E218|Staff |

| | | | |Rkfd) | |

| |

|6 |Oct 02 |T | |Case Study 5: Orientation to JNC 7 | |

|Lect 15 |Oct 03 |W |EXAM #1 (Lect 1-11) | |Staff |

|Lect 16 |Oct 04 |R |Pharmacotherapy of Hypertension I | |Cavallari |

|Lect 17 |Oct 05 |F |Pharmacotherapy of Hypertension II | |Cavallari |

| | |F | |Case Study 5: Orientation to JNC 7 | |

| | | | | |Cavallari |

|Week |Date |Day |Lecture Topic |Lab/Discussion Topic |Faculty |

|Lect 18 |Oct 10 |W |Pharmacotherapy of Lipid Disorders I | |Schoen |

|Lect 19 |Oct 11 |R |Pharmacotherapy of Lipid Disorders II | |Schoen |

|Lect 20 |Oct 12 |F |Chemistry of Drugs Used for Lipid Disorders | |Bruzik |

| | |F | |Case Study 6: Hypertension |Cavallari |

| |

|8 |Oct 16 |T | |Case Study 7: Lipid Therapeutics |Schoen |

|Lect 21 |Oct 17 |W |Antiplatelet Pharmacology | |Dr. Shek |

|Lect 22 |Oct 18 |R |Oral Anticoagulant Drugs I | |Nutescu |

|Lect 23 |Oct 19 |F |Parenteral Antithrombotics | |DiDomenico |

| | |F | |Case Study 7: Lipid Therapeutics |Schoen |

| |

|9 |Oct 23 |T | |No Lab / Disc this Week | |

| |Oct 24 |W |EXAM #2 (Lect 12-22) | |Staff |

|Lect 24 |Oct 25 |R |Oral Anticoagulant Drugs II | |Nutescu |

|Lect 25 |Oct 26 |F |Oral Anticoagulant Drugs III | |Nutescu |

| | |F | |No Lab / Disc this Week | |

| | | | | | |

|Lect 26 |Oct 31 |W |Pediatric Cardiology I | |Kraus |

|Lect 27 |Nov 01 |R |Pediatric Cardiology II | |Kraus |

|Lect 28 |Nov 02 |F |Beta Adrenergic Antagonists, Nitrates | |Katz |

| | |F | |Case Study 8: Oral Anticoagulants |Nutescu |

|Week |Date |Day |Lecture Topic |Lab/Discussion Topic |Faculty |

|Lect 29 |Nov 07 |W |Angina | |Groo |

|Lect 30 |Nov 08 |R |Acute Coronary Syndrome I | |DiDomenico |

|Lect 31 |Nov 09 |F |Acute Coronary Syndrome II | |DiDomenico |

| | |F | |No Lab / Disc this Week | |

| |

|12 |Nov 13 |T | |Case Study 9: Angina and Acute Coronary|DiDomenico |

| | | | |Syndrome | |

|Lect 32 |Nov 14 |W |Pharmacotherapy of Chronic Heart Failure I | |Groo |

|Lect 33 |Nov 15 |R |Pharmacotherapy of Chronic Heart Failure II | |Groo |

|Lect 34 |Nov 16 |F |Pharmacotherapy of Chronic Heart Failure III | |Groo |

| | |F | |Case Study 9: Angina and Acute Coronary|DiDomenico |

| | | | |Syndrome | |

| |

|13 |Nov 20 |T | |No Lab / Disc this Week | |

| |Nov 21 |W |EXAM #3 (Lect 23-31) | |Staff |

| |Nov 22 |R |Thanksgiving holiday: No classes | | |

| |Nov 23 |F |Thanksgiving holiday: No classes | | |

| | |F | |No Lab / Disc this Week | |

| |

|14 |Nov 27 |T | |Case Study 10: Heart Failure | |

|Lect 35 |Nov 28 |W |Arrhythmias and Antiarrhythmic Drugs I | |Bauman |

|Lect 36 |Nov 29 |R |Arrhythmias and Antiarrhythmic Drugs II | |Bauman |

|Lect 37 |Nov 30 |F |Arrhythmias and Antiarrhythmic Drugs III | |Bauman |

| | |F | |Case Study 10: Heart Failure |Groo |

|Week |Date |Day |Lecture Topic |Lab/Discussion Topic |Faculty |

|Lect 38 |Dec 05 |W |Arrhythmias and Antiarrhythmic Drugs IV | |Bauman |

|Lect 39 |Dec 06 |R |Pharmacology of Vasoactives | |DiDomenico |

|Lect 40 |Dec 07 |F |Acute Decompensated Heart Failure | |DiDomenico |

| | |F | |Case Study 11: Arrhythmias |Bauman |

| |

|16 |Dec 11 |T |EXAM #4 (Lect 32-40; 11:30am – 1:30 pm) | | |

INSTRUCTORS

|Name |Email |Room |Telephone |

| | | | |

|Dr. Jerry Bauman |jbauman@uic.edu |PHARM 145 |(312) 996-3267 |

|Dr. Karol Bruzik |kbruzik@uic.edu |PHARM 593 |(312) 996-4576 |

|Dr. Larissa Cavallari |humma@uic.edu |PHARM 125A |(312) 996-0886 |

|Dr. Robert DiDomenico |rdidom1@uic.edu |CSB 353 |(312) 996-0898 ext 1 |

|Dr. Vickie Groo |vjust@uic.edu |CSB 353 |(312) 413-0928 |

|Dr. Birgit Jaki |bjaki@uic.edu |PHARM 425 |(312) 996-5232 |

|Dr. Donna Kraus |dkraus@uic.edu |PHARM 121 |(312) 996-0895 |

|Dr. Edith Nutescu |enutescu@uic.edu |CSB 315 |(312) 996-0880 |

|Dr. Jimmy Orjala |orjala@uic.edu |MBRB 3170 |(312) 996-5583 |

|Dr. R. Francis Schlemmer |schlemm@uic.edu |PHARM 289 |(312) 996-9264 |

|Dr. Marieke Schoen |marieke@uic.edu |PHARM 184F |(312) 996-2965 |

|Dr. Eugene Shek |eugene.shek@ | |(847) 938-0428 |

TEACHING ASSISTANTS

|Name |Email |

| | |

|Mr. Daniel Colunga-Hernandez |ccolun2@uic.edu |

|Ms. Laura Gauthier |lgauth3@uic.edu |

|Ms. Mary Ellen Molloy |mmollo2@uic.edu |

|Mr. Brian Pereira |bperei2@uic.edu |

You are encouraged to contact instructors and TAs by e-mail as much as possible.

P4 STUDENT MENTORS/FACILITATORS

|Name |Module |Email |

|None | | |

TEAM LEADERS

|Name |Email |Room |Telephone |

| | | | |

|Dr. Norman Katz |nlkatz@uic.edu |PHARM 235 |(312) 996-0573 |

TEXT BOOKS

|Required |

| |

|Williams DA, Lemke TL, editors. Foye’s Principle of Medicinal Chemistry 6th edition. Baltimore, MD: Lippincott Williams & Wilkins; 2007.|

|DiPiro JT, Talbert RL, Yee GC, Matze GR, Wells BG, Posey LM, editors. Pharmacotherapy - A Pathophysiologic Approach 8th edition. |

|Stamford, CT: Appleton & Lang; 2011. |

| Katzung BG. Basic & Clinical Pharmacology 12th edition. New York, NY: McGraw-Hill; 2012. |

(These are texts used for the PDAT I to PDAT VIII series). They are available at the UIC Medical Bookstore and through various online booksellers; both the pharmacotherapy and pharmacology texts are available online at UIC .

Optional

|Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK Corelli RL, Williams BR, editors. Applied Therapeutics: The Clinical |

|Use of Drugs Tenth edition. Baltimore, MD: Lippincott Williams & Wilkins (LWW); 2012. |

|Harvey RA, Champe PC, Finkel R, Cubeddu L, Clarke MA, Editors. Lippincott’s Illustrated Reviews: Pharmacology, Fifth Edition. Baltimore,|

|MD: Lippincott Williams & Wilkins (WW); 2011. |

| |

| |

LAB - DISCUSSION GROUPS

Chicago

When you registered for this class, you were placed into one of 10 Lab / Discussion sections. Five sections have Lab / Discussion on Tuesday and five have Lab / Discussion on Friday. We reorganized the five Tuesday sections and the five Friday sections into four larger groups Each of the four larger Tuesday groups is assigned to either room 470, 498, 570 or 598. Similarly, each of the four larger Friday groups is assigned to one of Rooms 470, 498, 570 or 598. We may instruct all the Tuesday or Friday student groups to meet together in Room 134-3.

We have further divided up each large group into Lab / Discussion study groups of 4 or 5 individuals. These study group assignments cannot be changed except for extreme reasons and will remain in place for the duration of the course. If there is some big problem in a Lab / Discussion group, notify Dr. Katz. We are not unreasonable people, and we don’t expect you to suffer in silence if something is wrong.

The Lab / Discussion study groups are designated by letters within rooms on Tu or F. Thus, "T 470 A" means you are in Lab / Discussion group A in Room 470 on Tuesdays. "F 598 D" means you are in Lab / Discussion group D in Room 598 on Fridays.

If you miss a Lab / Discussion session for a good reason, such as an illness or legal reason, then you must get permission from the course coordinator to attend the alternate day. For example, if you normally attend on Tuesday, then you may ask to attend Friday’s session. If you attend on Friday, then you would have to be able to anticipate a problem or conflict in advance and ask to be allowed to attend Tuesday’s session. The course coordinator will assign you to a group for that day only. We will only permit these changes only for very good reasons, and we reserve the right to require appropriate documentation from you. If you miss the recitation and are unable to come on the other day, then your score for the day will be zero.

We will notify you (handouts, posting, Blackboard, etc) to inform you of your group assignment. Generally, there will be one TA assigned to each room on each day. You should know which TA is responsible for your Lab / Discussion room on your day.

No make-up quizzes will be permitted.

Rockford

When you registered for this class, you were placed into one Lab / Discussion section.

We have further divided up this large group into Lab / Discussion study groups of 3 or 4 individuals. These study group assignments cannot be changed except for extreme reasons and will remain in place for the duration of the course. If there is some big problem in a Lab / Discussion group, notify Dr. Katz. We are not unreasonable, and we don’t expect you to suffer in silence if something is wrong.

The Lab / Discussion study groups are designated by letters within rooms on Friday. Thus, "F” E211 A means you are in Lab / Discussion group A in Room E211 on Friday (F).

We will notify you (handouts, posting, Blackboard, etc) to inform you of your group assignment. Generally, there will be one TA assigned to each room on each day. You should know which TA is responsible for your Lab / Discussion room on your day.

No make-up quizzes will be permitted.

EVALUATION PROTOCOL

You can “drop” a quiz. There will be 10 evaluated Lab / Discussion sessions (quizzes or case assignments), three (3) one-hour midterm examinations and one (1) two-hour final examination. The quizzes or case study assignments will be valued at 20 points each. The lowest of the 10 evaluated quiz/case grades will be dropped IF you complete all faculty and course evaluations. That dropped score will be replaced with the average of the remaining nine (9) grades. If you score very poorly on a quiz or case study, or miss a recitation entirely, you should be sure to complete all of the evaluations so that your lowest score is dropped and replaced with the average of the remaining quiz scores. Evaluations will be sent electronically throughout the semester. Neither the course coordinators, nor the instructors, nor the team leader can access the evaluations directly. We merely receive the names of students from the Office of Academic Affairs who have not completed all of the evaluations; we will use that list to determine who is allowed to drop a score. No student can earn more than one dropped Lab / Discussion.

The point distribution below should be used as a guide. The final distribution, however, depends on the actual number of examinations, quizzes, and lab/discussion assignments:

|First Hourly Examination |33 questions |5 points per question |165 points |

|Second Hourly Examination |33 questions |5 points per question |165 points |

|Third Hourly Examination |27 questions |5 points per question |135 points |

|Final Examination |27 questions |5 points per question |135 points |

|Lab / Discussion |10 evaluated |20 points per quiz or case study |200 points |

| | | |[pic] |

| | | |800 points |

TYPE OF EXAMINATION QUESTIONS

Problem-solving questions requiring short, concise answers that can involve chemical structures and models for drug-receptor/enzyme interactions, matching and/or multiple choice questions will be used.

It is the policy of the PHAR 402 course coordinators NOT to return completed, graded examinations. Scores will be posted on Blackboard. Your graded examination and Scantron sheet will, however, be available for your inspection. You can review the answer key and your exam by contacting Dr. Katz to establish a mutually convenient time that you can meet together.

GRADING SYSTEM

A minimum of 60% of the total points (i.e., 480 points) is required to receive a passing grade. All students scoring above 90% of the total points will receive a grade of A. Grades of A, B, C and D will be assigned by the course coordinators for students receiving 60 - 90% of the total points. The final cut-off scores for each grade will be determined based on the overall performance of the class as well as the difficulties of the examinations given this year.

Religious Holidays

Students will be allowed observance of religious holidays, as defined by the UIC Senate and the UIC College of Pharmacy Student Handbook. The course coordinator must be notified as directed by the following policy:

The faculty of the University of Illinois at Chicago shall make every effort to avoid scheduling examinations or requiring that student projects be turned in or completed on religious holidays. Students who wish to observe their religious holidays shall notify the faculty member by the tenth day of the semester of the date when they will be absent unless the religious holiday is observed on or before the tenth day of the semester. In such cases the student shall notify the faculty member at least five days in advance of the date when he/she will be absent. The faculty member shall make every reasonable effort to honor the request, not penalize the student for missing the class, and if an examination or project is due during the absence, give the student an exam or assignment equivalent to the one completed by those students in attendance. If the student feels aggrieved, he or she may request remedy through the campus grievance procedure.

DISABILITY SERVICES STATEMENT

If you are a student with a disability who requires additional time to complete midterm and final examinations, you will be accommodated in accordance with the written instructions provided to the course coordinator by the Office of Disability Services. It is your responsibility to consult that Office and obtain written instructions for appropriate accommodations to be given to the course coordinator at least one week prior to the first midterm examination.

RULES AND GUIDELINES

1. Professional Behavior: Attendance, participation, and behavior are expected to meet the standards of professional performance, and will be evaluated as such. Professional standards include promptness, cooperation, and dedication to learning, presenting oneself appropriately, oral and written communication, ethical behavior, and assuming responsibility for your behavior and learning.

2. Attendance Policy. Students are expected to attend class and participate in the lecture, lab / discussion, quiz or examination at the times specified. The instructors and teaching assistants will inform you of their office hours if they wish to specify certain hours. Questions concerning lecture content should be discussed directly with the given lecturer at a mutually agreed upon time or by email. All other questions, including any questions concerning grading, should be discussed with the course coordinator.

3. Exam Policy

a. All examinations are closed book and quizzes can be closed or open book

b. Exams will start promptly at the beginning of the class time. Students are strongly encouraged to arrive promptly at the scheduled exam time to avoid disturbing other students and to take advantage of the allotted test time.

c. If a student is late for an examination, then, providing no student has exited the room, the late arriving student you may be permitted to take the examination but will not be granted extra time except at the digression of the course coordinator. Once the first student finishes an examination and exits the examination room, late arrivers will not be permitted to sit for the examination. The exam will be counted as a missed examination for such late arriver. Rules for determining if a make-up examination can be administered will then apply.

d. Failure to attend a scheduled exam/quiz does not automatically grant the student the right to take the exam at a later date.

e. No exam will be given prior to the scheduled exam date. All make-ups must be scheduled within 48 hours of the original scheduled exam date, if possible.

f. All requests for re-grades of quizzes or exams should be made in writing (email works well for this) to the instructor of record and copied to the course coordinator within 5 class days after a quiz/exam has been returned or a student has viewed the quiz/exam. Students have 5 class days after the start of the spring semester to request a re-grade of the final examination. It is the student’s responsibility to notify the course coordinator of any grading error.

g. Students will be permitted to make up examinations missed because of illness, mandatory religious obligations, other unavoidable circumstances or college/university-sponsored activities. Course coordinators will not provide make up exams to students who leave for a sponsored activity early or stay beyond the sponsored activity dates.

h. Students must take exams as scheduled. If a personal emergency or illness occurs, students must notify the course coordinator as soon as possible, prior to the exam, if possible. Students may be required to present evidence of emergent situation, such as a physician’s note, court order, etc. The instructor reserves the right to refuse to give a make-up exam without satisfactory evidence of illness or emergency.

i. An alternate final examination will be provided for students who are representing the college by attending a professional meeting during the regular week of final exams. The alternate final exam will be scheduled immediately after the professional meeting ends. We will not accommodate students who decide to stay beyond the meeting dates for vacations. Students who miss the regular final and the scheduled make-up final will receive INC grades and will have to resolve the matter in January after the new semester starts. Students who miss the final examination for other reasons will receive INC grades for the course and will have to resolve the matter in January after the new semester starts.

4. COPYRIGHT INFORMATION

Written materials, images, and media used in Phar 402 are restricted to students’ personal educational use. Copying, distributing, or placing them on the internet or using them for purposes other than personal use is prohibited. Violations will be dealt with severely up to and including recommendation of dismissal from the college.

Academic Integrity:

As students seeking to enter a profession that enjoys a high degree of trust among the public, honesty and integrity should be among your most cherished core values. When you enter the pharmacy profession, you will be carrying forward the long tradition of integrity that has earned the high level of trust the public accords this profession, your predecessors and you. We expect you to display integrity in all your academic pursuits, including this course, and to be true to your pledge of professionalism oath as a pharmacist. See the student handbook at .

Academic dishonesty includes all forms of cheating, plagiarism (copying the work of others and representing it as your own), giving other students your work and allowing them to represent it as their own, lying to faculty and/or TAs about reasons for missing exams, or other dishonest actions. No form of academic dishonesty is acceptable in the college. Cheating and other forms of dishonesty demean you individually and are demeaning to your fellow students and to your chosen profession. We take it very seriously. If you do engage in academic dishonesty of any form, and we catch you, we will follow the procedures outlined at .

Please realize that in Phar 402 the coordinator will deal with academic dishonesty in the harshest way available, up to and including recommending that the offender be dismissed from pharmacy school. To discourage any temptation to cheat on examinations or academic work, we will use various clandestine strategies such as distributing multiple forms of an examination without your knowledge, assigning seating, etc. Things may not be what they appear to be when we are giving examinations. The easiest way to avoid any problems in the course and in your professional years is to do your own work.

Recordings

This course will be using the Echo360 video capture system. Lectures will be recorded that include audio and video of the instructor sequenced with lecture slides and annotations. A few hours following the lecture, students can access the video capture through the Phar 402 BlackBoard site. Although the video capture system is designed to record the lecture, student questions raised in class can also be captured. Also, conversations before or after class might be unintentionally recorded. Finally, recordings should be used as a supplement and are not a substitute for class attendance. There can be times that a class is not recorded (i.e. equipment issues, etc).

SIGNATURES

Section 438 of the "General Education Provisions Act" (as amended), entitled "Family Educational Rights and Privacy Act" (FERPA), protects inappropriate access to your personal records. By signing (or e-signing) a FERPA waiver, you voluntarily grant to designated individuals (e.g., course coordinators, faculty members, TAs) permission to return materials to your college mailboxes.

THE NEXT PAGE LIST THE COURSE OBJECTIVES

COURSE OBJECTIVES

Identify the sites at the neuronal synapses that can be regulated by drugs and explain how a given drug molecule may act to modify response.

Explain the basic steps in a classically chemically transmitting synapse such as neurotransmitter synthesis, storage, release, and inactivation. Explain how drugs can influence these steps.

Describe the major chemical and biochemical differences between neurotransmitter receptors.

Relate the structural features of a compound to its receptor selectivity and activity.

Explain general principles of chemical transmission: denervation hypersensitivity, presynaptic modulation, postsynaptic modulation, termination of transmitter action.

Describe the physiological role, anatomic composition, and divisions of the autonomic nervous system.

List the neurotransmitters of the autonomic nervous system and associate them with their anatomical location.

List the receptors and receptor-subtypes of the sympathetic nervous system and predict the responses to activation of the sympathetic nervous system.

Determine desired therapeutic outcomes for patients with cardiovascular disease.

Formulate a therapeutic regimen involving prescription, non-prescription or non-pharmacological medications for patients with cardiovascular disease (e.g., recommend alteration of prescribed drug regimen, if necessary; select drug).

Define factors to consider when determining therapeutic outcomes for a patient with cardiovascular disease.

Formulate a monitoring plan to evaluate effectiveness of therapy and prevent adverse drug effects in patients being treated for cardiovascular disease.

List the necessary monitoring and screening procedures (e.g., blood pressure, glucose levels, and drug levels) for patients with cardiovascular disease or those at risk for cardiovascular disease.

THE NEXT PAGE IDENTIFIES GENERAL OUTCOME ABILITIES MET BY THIS COURSE. ALL OUTCOME ABILITIES WERE ADOPTED BY THE COLLEGE FACULTY

General Outcome Abilities*

University of Illinois at Chicago

College of Pharmacy

|General Outcome Ability |Met By |

| | |

|1. |Conceptual Competence |Using physiological (e.g., homeostasis) and pharmacological concepts|

| | |(e.g., receptors) and illustrating how they can be exploited by |

| | |drugs for patient benefits |

|2. |Scientific Comprehension |Reviewing/discussing clinical trials and clinical care guidelines |

| | |for treatment of cardiovascular diseases |

|3. |Mathematical Competence |Calculating body mass index, glomerular filtration rate, etc. to |

| | |solve simulated patient problems |

|4. |Integrative Competence |Applying and synthesizing theoretical knowledge gained from the |

| | |lectures to design assessment and treatment plans for patients using|

| | |simulated cases |

|5. |Critical Thinking and Decision Making |Evaluating patient data to identify treatment goals (e.g., blood |

| | |pressure goals); Designing, reviewing, and evaluating treatment |

| | |regimens for patients using simulated cases |

|6. |Social Interaction |Working in groups to evaluate simulated patient cases, synthesize |

| | |data from materials discussed in lecture, communicate verbally as a |

| | |group to design a written treatment plan; Role playing a patient or|

| | |pharmacist in front of the class |

|7. |Responsible use of values and ethical principles |-------------------------------------------------- |

|8. |Social Awareness |--------------------------------------------------- |

|9. |Social responsibility and citizenship |--------------------------------------------------- |

|10. |Self Learning Abilities and Habits |Completing some recitations prior to lecture and thus using |

| | |self-directed learning to solve a patient case |

UIC Professional Competencies and Outcome Expectations

|II. Provide Pharmaceutical Care |

| | | |

|Display professional orientation, attitudes,| | |

|habits, and values required to render | | |

|pharmaceutical care. | | |

|C. Gather and organize patient(s medical | | |

|information to identify potential and/or | | |

|ongoing patient-related problems and the | | |

|root cause of the problems. | | |

|D. Collaborate with physicians, other health|3. Integrate information as needed to design,| |

|care professionals, patients, and/or their |implement, and evaluate patient-specific | |

|caregivers to formulate a pharmaceutical |pharmacotherapeutic regimens to prevent or | |

|care plan. |resolve medication-related problems and to | |

| |respond to information requests. | |

| |4. Recommend appropriate drug therapy (e.g., |a. Use knowledge of the basic pharmaceutical |

| |prescription, nonprescription, herbal). |sciences (i.e., medicinal chemistry, |

| | |pharmaceutics, pharmacodynamics, |

| | |pharmacogenomics, pharmacokinetics, |

| | |physiology) to select appropriate medications|

| | |based on patient’s medical needs. |

| | |b. Determine the appropriateness of a |

| | |prescription(s dose, dosage form, route of |

| | |administration and frequency of |

| | |administration. |

| | |c. Determine the appropriateness of a |

| | |nonprescription product or dietary |

| | |supplements, dosage, dosage form, route of |

| | |administration and frequency of |

| | |administration. |

| |5. Determine the appropriate drug delivery | |

| |system for the patient based on his/her | |

| |individual needs, characteristics, and | |

| |cultural orientation. | |

| |6. Evaluate and recommend medication doses and| |

| |dosage schedules based on the evaluation of | |

| |relevant patient factors, including age, lab | |

| |values, physiologic, pharmacodynamic, | |

| |pharmacokinetic and pharmacogenomic parameters| |

| |and concomitant drug therapy. | |

|E. Implement the pharmaceutical care plan to |4. Provide counseling to patients and/or their| |

|meet patient needs. |caregivers relative to proper therapeutic | |

| |self-management. l | |

|H. Maintain professional proficiency by | | |

|identifying and analyzing emerging issues, | | |

|products and services that may impact | | |

|patient-specific therapeutic outcomes. | | |

* Adapted from (Background Paper II: Entry-Level Curricular Outcomes, Curricular Content and Educational Process(, American Journal of Pharmaceutical Education, Vol. 57: Winter 1993, pg. 377-385

-----------------------

Tues

Aug 24

Week 1

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download